Edward S. Kim, MD, MBA

Lyudmila A. Bazhenova, MD, and D. Ross Camidge, MD, PhD, review the DESTINY-Lung01 and DESTINY-Lung02 trials, and the panel provides its impressions of the data.

The panel discusses the role of antibody-drug conjugates (ADCs) and the treatment of patients with HER2 non–small cell lung cancer.

Experts on HER2 non–small cell lung cancer provide clinical insights on biomarker testing challenges and the role of reflex testing.

A panel of thoracic oncologists introduce themselves and discuss biomarker testing strategies and the diagnosis of HER2 non–small cell lung cancer (NSCLC).

Richard Kim, MD, discusses a real-world investigation of long-term responses with regorafenib in metastatic colorectal cancer.

Experts discuss the challenges of the ongoing cisplatin and carboplatin shortages in the United States and detail how they are adapting in their practices.

Edward S. Kim, MD, MBA, discusses drug shortages in cancer care, detailing how City of Hope has continued to establish efforts to mitigate the effects of these shortages.

Edward S. Kim, MD, MBA, discusses the importance of the Bridging the Gaps in Lung Cancer meeting, and expands on the importance of educating clinicians on how to best implement new developments within lung cancer to address these gaps in care.

Edward S. Kim, MD, MBA, discusses the importance of improving representation in clinical trials.

Edward S. Kim, MD, MBA, discusses the investigation of LP-300 plus chemotherapy in the phase 2 HARMONIC trial in patients with advanced lung adenocarcinoma.

Drs Edward S. Kim and Alexander Spira answer viewer questions on ADCs in non-small cell lung cancer.

A discussion on how ADCs affect current standards of care in the non-small cell lung cancer treatment landscape.

Alexander Spira, MD, PhD, FACP, and Edward S. Kim, MD, MBA, shift their focus to the use of antibody-drug conjugates in non-small cell lung cancer treatment with a review of ADC clinical trial data.

Edward S. Kim, MD, MBA, and Alexander Spira, MD, PhD, FACP, provide an overview of antibody-drug conjugates, including mechanism of action, historical milestones in development, and the approved ADCs for non–small cell lung cancer treatment.